Document is current
Any future updates will be listed below
-
Authors
Barakzie, Aarazo
van der Steen, Wouter
Jansen, A. J. Gerard
Roozenbeek, Bob
Donkel, Samantha J.
van der Lugt, Aad
Lingsma, Hester
Dippel, Diederik W. J.
Cate, Hugo ten
de Maat, Moniek P. M.
,
-
Funding
Funding for this research was provided by:
Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium, which is supported by the Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation (CVON2015-01, CVON2015-01, CVON2015-01, CVON2015-01, CVON2015-01, CVON2015-01, CVON2015-01, CVON2015-01, CVON2015-01)
the Brain Foundation Netherlands (HA2015.01.06, HA2015.01.06, HA2015.01.06, HA2015.01.06, HA2015.01.06, HA2015.01.06, HA2015.01.06, HA2015.01.06, HA2015.01.06)
the Ministry of Economic Affairs by means of the PPP Allowance made available by Top Sector Life Sciences and Health to stimulate public–private partnerships (LSHM17016, LSHM17016, LSHM17016, LSHM17016, LSHM17016, LSHM17016, LSHM17016, LSHM17016, LSHM17016)
unrestricted funding by Stryker, Medtronic, and Cerenovus
- License Information
-
More Information
Article History
Received: 7 March 2025
Revised: 28 May 2025
Accepted: 30 May 2025
First Online: 26 June 2025
Declarations
:
: Recommended Competing Interests Statement: The authors declare the following competing interests. This study was funded by the Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium, supported by the Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation (CVON2015-01: CONTRAST); the Brain Foundation Netherlands (HA2015.01.06); and the Ministry of Economic Affairs through the PPP Allowance (LSHM17016). The study also received unrestricted funding from Stryker, Medtronic, and Cerenovus. Regarding individual disclosures, AJGJ reports speaker’s fees and travel cost payments from 3SBio, Amgen, and Novartis, international advisory board membership for Novartis, and research funding from CSL Behring, Principia, SOBI, and Argenx, all unrelated to this study. HtC reports consultancy fees from Galapagos, Novostia, Alveron, AstraZeneca, and research support from Bayer. HtC is a shareholder in Coagulation Profile, a UM spinoff company, with all revenues allocated to CARIM for research purposes. D.W.J.D. and A.v.d.L. report grants from the Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organisation for Health Research and Development, and unrestricted grants from Cerenovus, Medtronic USA Inc, Penumbra Inc, Stryker European Operations BV, and Thrombolytic Science, LLC. C.B.L.M.M. reports a grant from the Dutch Heart Foundation and an unrestricted grant from Stryker Corporation. All other authors declare no competing interests.
